RxCelerate launches RxPlorer™: A new protein metastate discovery platform, unlocking new possibilities for screening against undruggable targets
• Cutting-edge platform technology leveraging advanced molecular dynamics to uncover protein metastates and reveal novel binding sites in difficult to target proteins.
• Combining RxPlorer™ with our in vitro capabilities, RxCelerate can deliver rapid hit identification and screening in 2 months.
Cambridge, UK and Cambridge, MA – 24/3/26 1pm GMT